Core Insights - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry, focusing on high-quality technological supply and policy support to enhance innovation and produce more effective drugs [1][2] Group 1: Government Initiatives - The government aims to strengthen original innovation and tackle key core technologies in the biopharmaceutical sector, leveraging both government and market resources to foster innovation [2] - There is a significant market potential in the health industry, with a focus on identifying innovative drug projects with high clinical value and transformation potential [1][2] Group 2: Research and Development - The government encourages collaborative research efforts targeting new drug targets, compounds, and mechanisms, aiming to produce major original achievements and cultivate high-end talent in life sciences [1] - The establishment of shared research platforms is promoted to accelerate the transformation of biopharmaceutical innovations, providing comprehensive support for the entire research and development cycle [2] Group 3: Industry Collaboration - The government advocates for deepening international cooperation among enterprises to enhance innovation and competitiveness in the biopharmaceutical sector [1] - There is a call for optimizing the operational models of innovation platforms to create replicable and scalable practices [2]

Market Overview - The Hang Seng Index (HSI) closed at 25,135.31, down by 30.63 points or 0.12% on August 20 [1] - The index reached a high of 25,193.11 and a low of 25,028.31 during the trading session, with a trading volume of 43.495 million shares [1] Major Blue-Chip Stocks - HSBC Holdings closed at HKD 102.118, up by 2.63% compared to the previous close [2] - Tencent Holdings closed at HKD 591.523, with a slight increase of 0.17% from the previous close [2] Stock Performance Summary - Tencent Holdings (00700) latest price is HKD 590.500, down by 0.34% [3] - Alibaba Group (09988) latest price is HKD 117.500, down by 0.68% [3] - HSBC Holdings (00005) latest price is HKD 99.500, up by 0.45% [3] - Meituan (03690) latest price remains unchanged at HKD 120.800 [3] - Pinduoduo (09992) saw a significant increase, closing at HKD 316.000, up by 12.54% [3]

调研中，李强主持召开座谈会。听取有关企业和投资、研发、医疗机构负责人发言后，李强指出，生物 医药产业既是战略性新兴产业，也事关人民健康福祉。要加强原始创新和关键核心技术攻关，发挥政府 和市场两方面作用，充分调动各类资源，凝聚创新合力，尽快取得更大突破。要注重运用人工智能全面 赋能产业发展，提高药物研发、临床试验、诊断治疗、生产流通等环节智能化水平。要强化产品研发、 审评审批、管理使用等政策衔接和协同配合，优化药品集采和谈判议价机制，加大高水平创新药应用指 导力度。李强强调，要依靠创新促进中医药振兴发展，充分运用现代科学的理论、技术、材料等，深化 中医药基础理论、诊疗规律、作用机理的研究阐释，丰富治疗方法，推进中医药现代化、产业化。 原标题：李强在北京调研生物医药产业发展时强调加大高质量科技供给和政策支持着力推动生物医药产 业提质升级 新华社北京8月20日电中共中央政治局常委、国务院总理李强8月20日在北京调研生物医药产业发展情 况。他强调，要深入贯彻习近平总书记关于生物医药产业发展的重要指示精神，加大高质量科技供给和 政策支持，充分发挥企业创新主体作用，着力推动生物医药产业提质升级，研发生产更多优质高效的好 ...

Core Insights - The Chinese government emphasizes the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry, aiming for the development of more effective new drugs to improve public health [2][3] Group 1: Government Initiatives - The government aims to accelerate the biopharmaceutical sector by increasing technological innovation and focusing on new targets, compounds, and mechanisms [2] - There is a significant market potential in the health industry, with a strong emphasis on identifying innovative drug projects with high clinical value and conversion potential [2][3] - The government encourages the cultivation of quality enterprises and provides policy support in areas such as talent and financing, while promoting international cooperation [2] Group 2: Research and Development Focus - The government stresses the importance of original innovation and tackling key core technologies, leveraging both government and market resources to foster innovation [3] - There is a call for the integration of artificial intelligence to enhance various stages of drug development, clinical trials, and production processes [3] - The government aims to modernize and industrialize traditional Chinese medicine by applying modern scientific theories and technologies [3]

Core Changes - Shareholder Change: Baker Brothers Life Sciences, L.P. and its affiliates reduced their shareholding from 8.06% to 7.99%, a decrease of 0.07 percentage points [1] - Share Count Unchanged: The number of shares held remains at 115,666,055, indicating passive dilution [1] Reason for Change - Date: August 19, 2025 [1] - Specifics: The company's subsidiary BG NC 2, Ltd. transferred 13 million common shares to a custodian in exchange for an equivalent number of American Depositary Shares [1] - Purpose: This transfer is intended to fulfill unvested equity awards under the 2016 option and incentive plan [1] Important Notes - No Change in A-Shares: This change does not affect the number of A-shares [1] - No Trigger for Mandatory Offer: The change does not trigger any mandatory offer obligations [1] - Governance Structure Unchanged: There is no alteration in the company's governance structure [1] - No Need for Disclosure: There is no requirement to disclose an equity change report or related documents [1] - Passive Dilution: The change is classified as passive dilution due to share issuance, with no actual change in the number of shares held by the shareholder [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於持股5%以上 股東權益變動觸及1%刻度的提示性公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年8月20日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、 ...

一、 信息披露义务人及其一致行动人的基本信息 美股代码：ONC 百济神州有限公司 关于持股5%以上股东权益变动 触及1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 | 信息披露义务人名称 | | | | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | --- | --- | --- | | Baker | Brothers | | Life | ☐ ☐ | 控股股东/实控人 控股股东/实控人的一致 | 不适用 | | Sciences, | 及 L.P. | 其 | 联 | 行动人 | | ☑ | | 属实体 | | | | ☑ | 其他直接持股股东 | | 二、 权益变动触及 1%刻度的基本情况 百济神州有限公司（以下简称"公司"）的子公司 BG NC 2, Ltd.于 2025 年 8 月 19 日（美国东部时间）向公司的托管公司移交 13,000,000 股公司的普通股， 用以换取相应数量的美国存托股份（每股美国存托股份相当于 13 股普通股），旨 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 0.91% as of August 20, 2025, with mixed performance among constituent stocks [1] - Heartbeat Medical led the gains with an increase of 3.13%, while Yuandong Biological experienced the largest decline [1] - The market for the Sci-Tech Medical ETF managed by Harvest saw a turnover rate of 24.05% and a transaction volume of 62.637 million yuan, indicating active trading [3] Group 2 - The latest scale of the Sci-Tech Medical ETF reached 263 million yuan, marking a one-month high and ranking first among comparable funds [3] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.157 million yuan, totaling 15.2382 million yuan [3] - The net value of the ETF increased by 56.59% over the past year, with the highest monthly return since inception being 23.29% [3] Group 3 - The total amount of business cooperation for innovative drugs in China is projected to reach 51.9 billion USD in 2024, with a record 1.25 billion USD upfront payment transaction between 3SBio and Pfizer in 2025 [4] - The Chinese innovative drug sector has seen a 25.02% increase year-to-date, ranking fourth among 31 industries, with a current PE ratio of 31.31 times [4] - The National Healthcare Security Administration has introduced a temporary management method for disease-based payment, promoting payment reform in the healthcare sector [4] Group 4 - As of July 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading companies including United Imaging and BeiGene [4][6] - The performance of individual stocks varied, with United Imaging down by 0.26% and BeiGene up by 0.95% [6] - Investors without stock accounts can access the Sci-Tech Medical ETF through the Harvest Sci-Tech Medical ETF linked fund [6]

Market Overview - The Hang Seng Index (HSI) closed at 24,951.48, down by 171.42 points or 0.68% as of August 19, 16:00 Eastern Time [1] - The index reached a high of 25,154.24 and a low of 24,938.43 during the trading session, with a trading volume of 39.6558 million [1] - The 52-week high for the index is 25,778.47, while the 52-week low is 17,034.99 [1] Blue-Chip Stocks Performance - Major blue-chip stocks mostly declined, with HSBC Holdings closing at HKD 99.581, up 0.54% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 588.764, down 0.63% compared to the Hong Kong close [2] Individual Stock Movements - Tencent Holdings (00700) saw a price of HKD 592.500, an increase of HKD 5.500 or 0.94%, but its ADR price was HKD 588.764, down HKD 3.736 compared to the Hong Kong close [3] - Alibaba Group (09988) closed at HKD 118.300, down HKD 0.300 or 0.25%, with an ADR price of HKD 116.979, down HKD 1.321 [3] - HSBC Holdings (00005) had a closing price of HKD 99.050, up HKD 0.600 or 0.61%, with an ADR price of HKD 99.581, up HKD 0.531 [3] - Xiaomi Group (01810) closed at HKD 52.400, down HKD 0.650 or 1.23%, with an ADR price of HKD 52.255, down HKD 0.145 [3] - AIA Group (01299) closed at HKD 74.200, down HKD 0.400 or 0.54%, with an ADR price of HKD 73.722, down HKD 0.478 [3]

Market Overview - On Monday, the three major US stock indices showed mixed results, while the Hang Seng Index ADR declined, closing at 25,129.61 points, down by 47.24 points or 0.19% compared to the Hong Kong closing [1]. Company Performance - Most large-cap blue-chip stocks experienced declines, with HSBC Holdings closing at HKD 99.979, up by 1.55% compared to the Hong Kong closing; Tencent Holdings closed at HKD 586.613, down by 0.07% [3]. - Notable stock movements include Alibaba W, which closed at HKD 118.600, up by 0.500 or 0.42%; and Xiaomi Group-W, which closed at HKD 53.050, up by 0.200 or 0.38% [4]. - Other significant performers include AIA Group, which closed at HKD 74.600, down by 0.350 or 0.47%; and JD Group-SW, which closed at HKD 124.000, up by 3.200 or 2.65% [4].